Astria Therapeutics Expands Board, Appoints New Director

The latest update is out from Astria Therapeutics (ATXS).

Astria Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed Sunil Agarwal, M.D. as a new director, starting April 8, 2024. Dr. Agarwal, who will also serve on the Science and Technology Committee, will be a Class III director until the next annual stockholders’ meeting. He will receive a stock option to purchase 28,200 shares at $11.40 each, vesting over three years, and an indemnification agreement similar to those of other directors.

See more data about ATXS stock on TipRanks’ Stock Analysis page.